BioSpace News Archive

The Tabulation is the final sum of the voting results of the Meeting and is the result of all the properly submitted proxies by shareholders in advance of the proxy cut-off time.

Mr. Yeung has over 17 years of experience in capital markets, private equity, and investment banking, holding various roles from equity research, sales, and banking.

CATO SMS is a consulting firm with more than 30 years of global experience to guide clinical development of biopharma pipelines.

New name to reflect the Biotech power of combining plant cell growth with elicitation of specific molecules to produce unique compounds of high human utility value.

Hillstream BioPharma Inc. (Nasdaq: HILS) (“Hillstream”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, announced the FDA granted Orphan Drug Designation to HSB-1216 for Uveal Melanoma (UM).

Each Warrant will entitle the holder to purchase Common Shares at an exercise price of CAD$0.375 per Common Share for a period of five years following the issuance date.

The study is taking place at Heading Health LLC (“Heading Health”) with Dr. Steve Levine, MD, as principal investigator. Recruitment for EBIQ-101 has been completed and the first patient dose is scheduled to occur later this week.

Kata® Clinical app supports clinical trials in the field of chronic lung diseases and can be customized to each trial’s individual requirements.

Today, the American Cancer Society’s National Consortium for Cancer Screening and Care (ACS National Consortium) announced nine consensus recommendations to accelerate recovery from the pandemic and improve the nation’s ability to provide quality cancer screening and care for all.

San Antonio-based Turn Medical, LLC, a medical device company founded by passionate people committed to delivering innovative solutions, has closed a bridge financing raise of $3.8 million for the ongoing commercialization of its Pronova-O2™ Automated Prone Therapy System.